Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation

Journal of Allergy and Clinical Immunology

Volumn 133, Issue 6, 2014, Pages

  Lougaris, Vassilios ^a   Baronio, Manuela ^a   Vitali, Massimiliano ^a   Tampella, Giacomo ^a   Cattalini, Marco ^a   Tassone, Laura ^a   Soresina, Annarosa ^a   Badolato, Raffaele ^a   Plebani, Alessandro ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

BTK; dendritic cells; STAT1; STAT3; TLR9

Indexed keywords

BRUTON TYROSINE KINASE; CD83 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; STAT1 PROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; B7 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; IBRUTINIB; LIPOPOLYSACCHARIDE; STAT3 PROTEIN;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION; ANTIGEN PRESENTING CELL; CLINICAL ARTICLE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; X LINKED AGAMMAGLOBULINEMIA;

BTK; DENDRITIC CELLS; STAT1; STAT3; TLR9;

AGAMMAGLOBULINEMIA; CYTOKINES; DENDRITIC CELLS; GENETIC DISEASES, X-LINKED; HUMANS; IMMUNOPHENOTYPING; LIPOPOLYSACCHARIDES; OLIGODEOXYRIBONUCLEOTIDES; PHENOTYPE; PROTEIN-TYROSINE KINASES; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 9;

EID: 84901801796     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.12.1085     Document Type: Article

References (24)

1. S. Tsukada, D.C. Saffran, D.J. Rawlings, O. Parolini, R.C. Allen, and I. Klisak et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia Cell 72 1993 279 290 (Pubitemid 23044942)
2. D. Vetrie, I. Vořechovský, P. Sideras, J. Holland, A. Davies, and F. Flinter et al. The gene involved in X-linked agammaglobulinemia is a member of the Src family of protein-tyrosine kinases Nature 361 1993 226 233 (Pubitemid 23034471)
3. A. Hussain, L. Yu, R. Faryal, D.K. Mohammad, A.J. Mohamed, and C.I. Smith TEC family kinases in health and disease - loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK FEBS J 278 2011 2001 2010
4. N.J. Horwood, A.M. Urbaniak, and L. Danks Tec family kinases in inflammation and disease Int Rev Immunol 31 2012 87 103
5. A.J. Mohamed, L. Yu, C.M. Bäckesjö, L. Vargas, R. Faryal, and A. Aints et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain Immunol Rev 228 2009 58 73
6. J. Gomez-Rodriguez, J.A. Readinger, I.C. Viorritto, K.L. Mueller, R.A. Houghtling, and P.L. Schwartzberg Tec kinases, actin, and cell adhesion [review] Immunol Rev 218 2007 45 64 (Pubitemid 47052304)
7. U. Schmidt, N. Boucheron, B. Unger, and W. Ellmeier The role of Tec family kinases in myeloid cells Int Arch Allergy Immunol 134 2004 65 78 (Pubitemid 38698100)
8. K. Fiedler, A. Sindrilaru, G. Terszowski, E. Kokai, T.B. Feyerabend, and L. Bullinger et al. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia Blood 117 2011 1329 1339
9. A. Khare, B. Viswanathan, R. Gund, N. Jain, B. Ravindran, and A. George et al. Role of Bruton's tyrosine kinase in macrophage apoptosis Apoptosis 16 2011 334 346
10. A.D. Koprulu, and W. Ellmeier The role of Tec family kinases in mononuclear phagocytes [review] Crit Rev Immunol 29 2009 317 333
11. Y. Bao, J. Zheng, C. Han, J. Jin, H. Han, and Y. Liu et al. Tyrosine kinase BTK is required for NK cell activation J Biol Chem 287 2012 23769 23778
12. D.J. Rawlings, D.C. Saffran, S. Tsukada, D.A. Largaespada, J.C. Grimaldi, and L. Cohen et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice Science 261 1993 358 361 (Pubitemid 23281007)
13. T.U. Marron, K. Rohr, M. Martinez-Gallo, J. Yu, and C. Cunningham-Rundles TLR signaling and effector functions are intact in XLA neutrophils Clin Immunol 137 2010 74 80
14. F. Honda, H. Kano, H. Kanegane, S. Nonoyama, E.S. Kim, and S.K. Lee et al. The kinase BTK negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils Nat Immunol 13 2012 369 378
15. K. Sochorová, R. Horváth, D. Rozková, J. Litzman, J. Bartunková, and A. Sedivá et al. Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia Blood 109 2007 2553 2556 (Pubitemid 46425901)
16. S.L. Doyle, C.A. Jefferies, C. Feighery, and L.A. O'Neill Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase J Biol Chem 282 2007 36953 36960
17. M.E. González-Serrano, I. Estrada-García, D. Mogica-Martínez, A. González-Garay, G. López-Herrera, and L. Berrón-Ruiz et al. Increased pro-inflammatory cytokine production after lipopolysaccharide stimulation in patients with X-linked agammaglobulinemia J Clin Immunol 32 2012 967 974
18. T.U. Marron, M. Martinez-Gallo, J.E. Yu, and C. Cunningham-Rundles Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines J Allergy Clin Immunol 129 2012 184 190
19. A.H. Dalpke, M.D. Lehner, T. Hartung, and K. Heeg Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance Immunology 116 2005 203 212 (Pubitemid 41368662)
20. L.A. Honigberg, A.M. Smith, M. Sirisawad, E. Verner, D. Loury, and B. Chang et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc Natl Acad Sci U S A 107 2010 13075 13080
21. M.F. De Rooij, A. Kuil, C.R. Geest, E. Eldering, B.Y. Chang, and J.J. Buggy et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia Blood 119 2012 2590 2594
22. E.S. Winer, R.R. Ingham, and J.J. Castillo PCI-32765: A novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies Expert Opin Investig Drugs 21 2012 355 361
23. R.H. Advani, J.J. Buggy, J.P. Sharman, S.M. Smith, T.E. Boyd, and B. Grant et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies J Clin Oncol 31 2013 88 94
24. J.R. Brown Ibrutinib in CLL and B cell malignancies Leuk Lymphoma 55 2014 263 269